Follow Blackstone to never miss an important update.
Blackstone is putting 1.5 billion dollars into the development of a weight-loss drug for Pfizer. This type of deal, known as life sciences funding, allows Blackstone to act like a lender for drug trials. Instead of traditional interest, the firm typically earns a percentage of the money made if the drug is eventually approved and sold.
This move shows how Blackstone is using its massive pool of cash to find returns outside of traditional real estate or stocks. By funding a high-demand area like obesity medicine, the firm is betting it can earn reliable income from the pharmaceutical industry's need for specialized capital.
Source: WSJ
Blackstone funds are partnering with professional services firm Aon to launch a new syndicate called Cortina within Lloyd's, the world's leading insurance market. Starting in January 2027, the group will provide capital for reinsurance, which is essentially insurance for insurance companies to help them manage large or unexpected claims.
This move fits Blackstone's broader strategy of expanding into the insurance and credit markets. By providing the financial backing for these policies, Blackstone can earn steady fees and put its massive pool of capital to work in a sector that is less tied to the ups and downs of the stock market.
Source: PRNewsWire
Blackstone President Jon Gray noted that the scale of AI infrastructure spending is becoming so large that it will require more equity financing, money from investors, rather than just borrowing. This shift is necessary because debt investors are starting to worry about having too much of their money tied up in a single sector.
This matters because Blackstone has made AI data centers its primary growth engine. If the firm has to use more of its own or its clients' cash instead of cheap borrowed money, it could change how it structures these massive deals. While the demand for AI power is high, the sheer size of the needed investment, estimated at 10 trillion dollars over five years across the industry, is beginning to test what the financial markets can handle.
Source: CNBC
Blackstone’s life sciences arm is providing 455 million dollars to co-fund a new heart pump program with Boston Scientific. The device, called VITALYST, is a miniature pump designed to help the heart move blood to vital organs during medical emergencies like heart attacks.
This deal shows how Blackstone uses its massive scale to act as a lender and partner for specialized healthcare projects that need heavy funding. While the dollar amount is small compared to Blackstone's total assets, it highlights the firm's strategy of finding high-growth niches outside of traditional real estate and private equity.
Source: Business Wire
Blackstone finalized the sale of 1.1 billion dollars in senior notes on November 2. The offering is split into 600 million dollars due in 2031 and 500 million dollars due in 2033. These notes are essentially corporate IOUs that allow the firm to raise cash today in exchange for regular interest payments and a full repayment at the end of the term. This filing confirms the details of a debt raise reported last week. For a firm that manages over a trillion dollars, this is a routine way to manage its own cash and funding costs. The interest rates are in line with current market levels and do not change the overall picture for the business.
Source: 8-K filing
Management has cleared its own profit targets for eight straight quarters. This pattern shows a team that sets a conservative bar and consistently finds ways to outpace it.
| Expectation | |
|---|---|
| EPS | $1.71 |
| Revenue | $4.26B |